我院2011-2013年抗肿瘤药使用分析

Analysis of the Utilization of Antitumor Drugs in Our Hospital from 2011 to 2013

目的:了解我院抗肿瘤药的使用情况及趋势。方法:结合我院肿瘤分类构成情况,采用用药频度(DDDs)和金额排序法对2011-2013年我院抗肿瘤药的应用情况进行分析。结果:各年度肺癌、乳腺癌、食管癌构成排序均居前3位。植物来源的抗肿瘤药及其衍生物、抗代谢药和其他抗肿瘤药各年度销售金额均居前3位,约占总销售金额的80%;多西他赛、紫杉醇销售金额连续3年均居前3位;各年度DDDs排序前3位均为卡培他滨、替吉奥、氟尿嘧啶。结论:我院抗肿瘤用药倾向于抗代谢药,而紫杉烷类、铂类应用也较多,但分子靶向药品种少、市场份额小。

OBJECTIVE： To investigate the application and trend of antitumor drugs in our hospital. METHODS： Combined with the composition of tumor, the utilization of antitumor drugs in our hospital from 2011 to 2013 was analyzed statistically in terms of consumption sum and DDDs. RESULTS： Top 3 tumors in the list of composition ranking were lung cancer, breast cancer and esophageal cancer for 3 consecutive years. Top 3 drugs varieties in the list of consumption sum were antitumor drug and its de- rivative, antimetabolites and other antitumor drug, which accounted for nearly 80% of total consumption sum. Docetaxel and pacli- taxel occupied the first 3 places in the list of consumption sum in 3 years. Top 3 drugs in the list of DDDs were capecitabine, S-1 and fluorouracil. CONCLUSIONS： Medication regimen tends to antimetabolites, while platinum and taxanes are used frequently. But the targeted drug is poor in variety and market share.